Cargando…

Mycophenolate Mofetil Use in Severe Myocarditis Complicating Systemic Lupus

Cardiac involvement represents an increasingly frequent complication in systemic lupus, with pericarditis being the most classic cardiac manifestation. However, the most severe and fatal form seems to be myocarditis. We present the case of a patient with systemic lupus complicated by cardiogenic sho...

Descripción completa

Detalles Bibliográficos
Autores principales: Allaoui, Abire, EL OUARRADI, Amal, Jabbouri, Rajaa, Naitelhou, Abdelhamid
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cureus 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9270891/
https://www.ncbi.nlm.nih.gov/pubmed/35812561
http://dx.doi.org/10.7759/cureus.25789
_version_ 1784744564672692224
author Allaoui, Abire
EL OUARRADI, Amal
Jabbouri, Rajaa
Naitelhou, Abdelhamid
author_facet Allaoui, Abire
EL OUARRADI, Amal
Jabbouri, Rajaa
Naitelhou, Abdelhamid
author_sort Allaoui, Abire
collection PubMed
description Cardiac involvement represents an increasingly frequent complication in systemic lupus, with pericarditis being the most classic cardiac manifestation. However, the most severe and fatal form seems to be myocarditis. We present the case of a patient with systemic lupus complicated by cardiogenic shock secondary to troponin-negative acute myopericarditis and successfully treated with mycophenolate mofetil and corticosteroid therapy. A 33-year-old woman with no past medical history presented with asthenia and inflammatory arthralgia. She was admitted in June 2021 for acute heart failure. Transthoracic cardiac ultrasound showed dilated cardiomyopathy with global hypokinesis (20-25% of ejection fraction) and right ventricular dysfunction without significant mitral and aortic valve disease. She had raised proBNP (pro-brain natriuretic peptide), low troponin, normochromic normocytic anemia at 10.4 g/dL, positive direct Coombs, lymphopenia at 460/mm(3), serum creatinine at 23.9 mg/L, and proteinuria/creatininuria 2.48 g/g. Cardiac magnetic resonance imaging (CMR) suggested the diagnosis of myopericarditis. The etiological assessment did not identify an infectious, toxic, or medicinal cause. The clinical picture suggested the possibility of an autoimmune disease. The patient presented with lesions suggestive of cutaneous vasculitis, with oral ulcers with polyarthritis. The autoimmune workup showed anti-nuclear antibodies at 1:1,280, anti-native DNA antibodies at 210 IU/mL (normal < 10 IU/mL), and positive anti-SM Abs. The diagnosis of lupus myopericarditis complicated by cardiogenic shock was made, which was associated with acute renal impairment. The patient was initiated on heart failure medications along with corticosteroids and mycophenolate mofetil. On day 15, the left ventricular ejection fraction improved to 45-50%, with clinical improvement in signs of heart failure and general condition. The existence of myopericarditis without obvious etiology, especially when there are extra-cardiac signs such as skin and joint involvement, should lead us to look for systemic lupus in order to start etiological treatment in addition to cardiac medical treatment. Until now, there is no standard treatment for lupus myocarditis, but the use of mycophenolate mofetil seems to be a promising treatment.
format Online
Article
Text
id pubmed-9270891
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Cureus
record_format MEDLINE/PubMed
spelling pubmed-92708912022-07-09 Mycophenolate Mofetil Use in Severe Myocarditis Complicating Systemic Lupus Allaoui, Abire EL OUARRADI, Amal Jabbouri, Rajaa Naitelhou, Abdelhamid Cureus Cardiology Cardiac involvement represents an increasingly frequent complication in systemic lupus, with pericarditis being the most classic cardiac manifestation. However, the most severe and fatal form seems to be myocarditis. We present the case of a patient with systemic lupus complicated by cardiogenic shock secondary to troponin-negative acute myopericarditis and successfully treated with mycophenolate mofetil and corticosteroid therapy. A 33-year-old woman with no past medical history presented with asthenia and inflammatory arthralgia. She was admitted in June 2021 for acute heart failure. Transthoracic cardiac ultrasound showed dilated cardiomyopathy with global hypokinesis (20-25% of ejection fraction) and right ventricular dysfunction without significant mitral and aortic valve disease. She had raised proBNP (pro-brain natriuretic peptide), low troponin, normochromic normocytic anemia at 10.4 g/dL, positive direct Coombs, lymphopenia at 460/mm(3), serum creatinine at 23.9 mg/L, and proteinuria/creatininuria 2.48 g/g. Cardiac magnetic resonance imaging (CMR) suggested the diagnosis of myopericarditis. The etiological assessment did not identify an infectious, toxic, or medicinal cause. The clinical picture suggested the possibility of an autoimmune disease. The patient presented with lesions suggestive of cutaneous vasculitis, with oral ulcers with polyarthritis. The autoimmune workup showed anti-nuclear antibodies at 1:1,280, anti-native DNA antibodies at 210 IU/mL (normal < 10 IU/mL), and positive anti-SM Abs. The diagnosis of lupus myopericarditis complicated by cardiogenic shock was made, which was associated with acute renal impairment. The patient was initiated on heart failure medications along with corticosteroids and mycophenolate mofetil. On day 15, the left ventricular ejection fraction improved to 45-50%, with clinical improvement in signs of heart failure and general condition. The existence of myopericarditis without obvious etiology, especially when there are extra-cardiac signs such as skin and joint involvement, should lead us to look for systemic lupus in order to start etiological treatment in addition to cardiac medical treatment. Until now, there is no standard treatment for lupus myocarditis, but the use of mycophenolate mofetil seems to be a promising treatment. Cureus 2022-06-09 /pmc/articles/PMC9270891/ /pubmed/35812561 http://dx.doi.org/10.7759/cureus.25789 Text en Copyright © 2022, Allaoui et al. https://creativecommons.org/licenses/by/3.0/This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
spellingShingle Cardiology
Allaoui, Abire
EL OUARRADI, Amal
Jabbouri, Rajaa
Naitelhou, Abdelhamid
Mycophenolate Mofetil Use in Severe Myocarditis Complicating Systemic Lupus
title Mycophenolate Mofetil Use in Severe Myocarditis Complicating Systemic Lupus
title_full Mycophenolate Mofetil Use in Severe Myocarditis Complicating Systemic Lupus
title_fullStr Mycophenolate Mofetil Use in Severe Myocarditis Complicating Systemic Lupus
title_full_unstemmed Mycophenolate Mofetil Use in Severe Myocarditis Complicating Systemic Lupus
title_short Mycophenolate Mofetil Use in Severe Myocarditis Complicating Systemic Lupus
title_sort mycophenolate mofetil use in severe myocarditis complicating systemic lupus
topic Cardiology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9270891/
https://www.ncbi.nlm.nih.gov/pubmed/35812561
http://dx.doi.org/10.7759/cureus.25789
work_keys_str_mv AT allaouiabire mycophenolatemofetiluseinseveremyocarditiscomplicatingsystemiclupus
AT elouarradiamal mycophenolatemofetiluseinseveremyocarditiscomplicatingsystemiclupus
AT jabbourirajaa mycophenolatemofetiluseinseveremyocarditiscomplicatingsystemiclupus
AT naitelhouabdelhamid mycophenolatemofetiluseinseveremyocarditiscomplicatingsystemiclupus